Insulet Expands its U.S. Financial Assistance Program for Current Users Impacted by COVID-19

Apr 16, 2020

Insulet Expands its U.S. Financial Assistance Program for Current Users Impacted by COVID-19

ACTON, Mass--(BUSINESS WIRE)--Apr. 16, 2020-- Insulet Corporation (NASDAQ: PODD) (Insulet or the Company), the global leader in tubeless insulin pump technology with its Omnipod® Insulin Management System, today announced an expansion of its U.S. financial assistance program for current customers who have been negatively impacted by COVID-19. Upon meeting certain financial criteria, a current customer may receive up to a six-month supply of products (60 Pods) free of charge.

“We know this economic downturn has the potential to affect many of our current customers and we want to help them through these unprecedented and challenging times,” said Shacey Petrovic, President and Chief Executive Officer. “Our Coronavirus response plan is guided by our fundamental principles of protecting the health and safety of our employees, preserving the well-being of the communities in which we live and work, and ensuring that customers have continued access to our life-sustaining medical therapy. Our Podders are part of our community and we are here for them.”

Insulet’s expanded financial assistance program is focused on current U.S. customers who have lost jobs and insurance as a result of the pandemic, are not covered by Medicaid or other insurance, and who meet certain financial criteria. The program is available through December 31, 2020 in the U.S. only in order to address the unique healthcare affordability challenges in the U.S. Current U.S. customers are asked to call the Insulet Customer Care team at 1 (800) 591-3455 and select Option 2 for assistance.

© 2020 Insulet Corporation. Omnipod is a registered trademark of Insulet Corporation. All rights reserved.

About Insulet Corporation:

Insulet Corporation (NASDAQ: PODD), headquartered in Massachusetts, is an innovative medical device company dedicated to making the lives of people with diabetes and other conditions easier through the use of its Omnipod product platform. The Omnipod Insulin Management System provides a unique alternative to traditional insulin delivery methods. With its simple, wearable design, the disposable Pod provides up to three days of non-stop insulin delivery, without the need to see or handle a needle. Insulet also leverages the unique design of its Pod by tailoring its Omnipod technology platform for the delivery of non-insulin subcutaneous drugs across other therapeutic areas. For more information, please visit: and

Forward-Looking Statement:

This press release may contain forward-looking statements concerning Insulet's expectations, anticipations, intentions, beliefs or strategies regarding the future. These forward-looking statements are based on its current expectations and beliefs concerning future developments and their potential effects on Insulet. There can be no assurance that future developments affecting Insulet will be those that it has anticipated. These forward-looking statements involve a number of risks, uncertainties (some of which are beyond its control) or other assumptions that may cause actual results or performance to be materially different from those expressed or implied by these forward-looking statements, and other risks and uncertainties described in its Annual Report on Form 10-K, which was filed with the Securities and Exchange Commission in February 2020 in the section entitled "Risk Factors," and in its other filings from time to time with the Securities and Exchange Commission. Should one or more of these risks or uncertainties materialize, or should any of its assumptions prove incorrect, actual results may vary in material respects from those projected in these forward-looking statements. Insulet undertakes no obligation to publicly update or revise any forward-looking statements.

Corporate Communications:
Angela Wiczek
Director, Corporate Communications
(978) 932-0611

Investor Relations:
Deborah R. Gordon
Vice President, Investor Relations
(978) 600-7717

Source: Insulet Corporation